Reply: Re: Harris L, Graham S, MacLachlan S, et al. Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England. J Med Econ. 2019;22(7):691-697

J Med Econ. 2021 Jan-Dec;24(1):864-865. doi: 10.1080/13696998.2021.1948733.

Authors

Linda Harris¹, Sophie Graham², Sharon MacLachlan², Alex Exuzides³, Saiju Jacob⁴

Affiliations

¹ Biohaven Pharmaceuticals, New Haven, CT, USA.
² Evidera, Hammersmith, UK.
³ Genentech, San Francisco, NC, USA.
⁴ University Hospitals Birmingham, Birmingham, UK.

PMID: 34266356
DOI: 10.1080/13696998.2021.1948733

No abstract available

Publication types

Letter
Comment

MeSH terms

England
Humans
Myasthenia Gravis* / drug therapy
Patient Acceptance of Health Care